Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer
Lola R. Nogueira(Research Institute Hospital 12 de Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Eva Ciruelos Gil(Hospital Universitario 12 De Octubre), Ainhoa Madariaga(Hospital Universitario 12 De Octubre), Sofía Aragón Sánchez(Research Institute Hospital 12 de Octubre), Laura Lema(Hospital Universitario 12 De Octubre), Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), Ana Maderuelo(Research Institute Hospital 12 de Octubre), Teresa Zumárraga(Research Institute Hospital 12 de Octubre), Consuelo Sanz(Research Institute Hospital 12 de Octubre), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Juan Montes(Research Institute Hospital 12 de Octubre), Yolanda Ruano(Hospital Virgen de la Salud)
Cited by 1
Related Papers
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
|Annals of Oncology|2021|294
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
|Journal of Clinical Oncology|2006|149
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <i>V600E</i> mutation
|The Journal of Experimental Medicine|2019|136